Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Asceli...
Redeye provides its initial take on Acarix’s Q2 report, which showed a year-on-year increase in both...
The sales number for Q2 had already been communicated and was slightly above our forecast.
* Sales -4% and adj. EBIT -11% vs ABGSCe * DOCS adoption 23% of municipalities * Consensus adj.
Redeye provides an initial comment on the Q2 2025 report from Catella.
* Sales -4% vs. ABGSCe at SEK 55m * EBITDA better than expected (SEK -0.
* Stable occupancy and positive net letting * Cons to lower estimates (rec.
* Q2 EBIT of SEK 315m, +11% vs. ABGSC and +7% vs. consensus * Announces buyback of bonds of max SEK ...
Redeye comments on Better Collective’s Q2-results which were slightly below our forecast owing mainl...
Redeye provides its initial take on Surgical Science’s Q2 2025 report, which aligned with its profit...
* Q2 in line, with automotive market and FX posing headwinds * Some uncertainty about targets, but v...
Redeye comments on SynAct Biopharma’s Q2 report. After a directed share issue, loan agreement with H...
Redeye provides an update following Paxman’s Q2 2025 report.
Investors House's Q2 report was overshadowed by the announcement that the board will propose an extr...
Redeye clarifies the changes in the fair value range.
- Report out 26 August - Q2e EBIT of SEK 103m - Onshore wind project (147 MW), Pienava in Latvia, so...
Redeye provides a research update following the Q2 report published by Cinclus earlier today.
Redeye strengthens its positive view of Formpipe following the Q2 report.
- Strong growth and gross margin continued in Q2'25 -EBIT revised up by 11% for '25e and 4% for '26e...
- Sales -3%, adj. EBIT +1% vs. ABGSCe - Continued uncertainty in the automotive sector driven by tar...
